Renaissance Capital logo

Alzheimer's biotech Alzheon files for a $81 million IPO

March 16, 2018
ALZH

Alzheon, a late-stage biotech developing small molecule therapies for Alzheimer's disease, filed on Friday with the SEC to raise up to $81 million in an initial public offering.

The Framingham, MA-based company was founded in 2013 and plans to list on the Nasdaq under the symbol ALZH. Alzheon filed confidentially on December 21, 2017. Citi, Piper Jaffray, Canaccord Genuity and JMP Securities are the joint bookrunners on the deal. No pricing terms were disclosed.